Clinical Trial Update: Study of Inhaled Nitric Oxide (iNO) and Respiratory Outcomes in Late Preterm Infants [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/3 trial evaluating inhaled nitric oxide for bronchopulmonary dysplasia in late preterm infants was terminated. Results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bronchopulmonary Dysplasia

Drugs mentioned

• Inhaled nitric oxide (nitric oxide)

Snippet

Sponsor: Tufts Medical Center | Conditions: Bronchopulmonary Dysplasia | Phase 2, Phase 3 | Status: TERMINATED | Results posted: 2017-07-19